**Manuscript Type:** Original Article

**Treatment implications of renal disease in patients with atrial fibrillation: the BALKAN-AF survey**

**Running head:** the BALKAN-AF survey: renal function

Monika Kozieł1,2,, Stefan Simovic3, Nikola Pavlovic4, Milan Nedeljkovic5,6, Aleksandar Kocijancic5, Vilma Paparisto7, Ljilja Music8, Elina Trendafilova9, Anca Rodica Dan10, Sime Manola4, Zumreta Kusljugic11, Gheorghe-Andrei Dan12, \*Gregory Y.H. Lip1,2,6,13, \*Tatjana S. Potpara5,6 on behalf of the BALKAN-AF Investigators.

\*Joint senior authors

1 Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom,

2Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Division of Medical Sciences in Zabrze, Medical University of Silesia, Zabrze, Poland,

3Cardiology Clinic, University Clinical Center of Kragujevac, Kragujevac, Serbia,

4Clinical Center Sestre Milosrdnice, Zagreb, Croatia,

5Cardiology Clinic, Clinical Center of Serbia, Belgrade, Serbia,

6School of Medicine, Belgrade University, Belgrade, Serbia,

7Clinic of Cardiology, University Hospital Center Mother Theresa, Tirana,Albania,

8Cardiology Clinic, University Clinical Center of Montenegro, University of Podgorica, Medical Faculty, Podgorica, Montenegro,

9National Heart Hospital, Coronary Care Unit, Sofia, Bulgaria,

10Colentina University Hospital, Cardiology Department, Bucharest, Romania,

11Clinic of Internal Medicine, Cardiology Department, University Clinical Center Tuzla, Medical Faculty, Tuzla,Bosnia and Herzegovina,

12Medicine University "Carol Davila", Colentina University Hospital, Bucharest,Romania,

13 Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

**Address for correspondence:**

Associate Professor Tatjana Potpara, MD, PhD, FESC

Cardiology Clinic, Clinical Center of Serbia, Visegradska 26, 11000 Belgrade, Serbia

Tel: +381 11 3616319, Fax: +381 11 3616319

Email: tanjapotpara@gmail.com; tatjana.potpara@med.bg.ac.rs

**Abstract**

**Background.** Atrial fibrillation (AF)often co-exists with renal function (RF) impairment. We investigated the characteristics and management of AF patients across creatinine clearance strata and potential changes in the use of non-vitamin K oral anticoagulants (NOAC) according to different equations for estimation of RF.

**Methods.** In this post-hoc analysis of the BALKAN-AF survey, patients were classified according to RF (Cockcroft-Gault formula) as: preserved/mildly depressed RF (P-RF) ≥50 ml/min, moderately depressed RF (MD-RF) 30-49 ml/min and severely depressed RF (SD-RF) <30 ml/min.

**Results.** Of 2,712 enrolled patients, 2,062 (76.0%) had data on RF. Patients with SD-RF and MD-RF were older, had higher mean value of European Heart Rhythm Association score, stroke and bleeding risk scores and more comorbidities than patients with P-RF (all p<0.05). They received oral anticoagulants (OAC), AF catheter ablation and electrical cardioversion less often than those with P-RF (all p<0.05). Rate control, no OAC, single antiplatelet therapy (SAPT) alone and loop diuretics were more prevalent in patients with SD-RF and MD-RF than in subjects with P-RF (all p<0.005). An important change in NOAC therapy could appear in <1% of patients (Modification of Diet in Renal Disease formula) and in <1% of patients (Chronic Kidney Disease Epidemiology Collaboration group formula).

**Conclusions.** Patients with SD-RF and MD-RF were older, more symptomatic, had higher stroke and bleeding risk and more comorbidities than those with P-RF. They were less likely to receive OAC and more likely to use rate control strategy, SAPT alone and no OAC than subjects with P-RF.

**Keywords:** atrial fibrillation, BALKAN-AF survey, creatinine clearance, oral anticoagulant therapy, renal function

**Introduction**

Atrial fibrillation (AF) is often accompanied by renal function (RF) impairment of various degree (1), co-existing with chronic kidney disease (CKD) in about 15-20% of patients (2), especially among the elderly and those with concomitant risk factors such as, for example, diabetes mellitus (DM), hypertension or obesity (3).

Kidney damage (i.e., albuminuria) or impaired kidney function [i.e., glomerular filtration rate (GFR) <60 mL/min/1.73 m²] for three months or more is defined as CKD (4). Estimated GFR (eGFR) may be calculated from the serum creatinine using various equations (1, 5), and the Kidney Disease: Improving Global Outcomes (KIDIGO) group endorsed Chronic Kidney Disease Epidemiology Collaboration group (CKD-EPI) equation (5). The CKD-EPI equation is less biased and more precise in GFR estimation than Cockcroft-Gault (CG) or MDRD (Modification of Diet in Renal Disease) (1). In case of management with non-vitamin K oral anticoagulants (NOACs), RF should be assessed by calculating creatinine clearance (CrCl) using the CG method as in most NOAC trials (6). Patients are eligible for NOACs if CrCl is ≥ 30 mL/min in case of dabigatran or CrCl is ≥ 15 mL/min in case of rivaroxaban, apixaban and edoxaban. Importantly, NOAC dose should be selected as per the drug label (6, 7).

There is a bidirectional interaction between AF and CKD. AF facilitates the development or progression of CKD, whereas decreased RF is associated with increased prevalence and incidence of AF. AF and CKD share common abnormal molecular signalling pathways contributing to their pathogenesis. There is a well-established inter-relationship between heart and the kidney, thus dysfunction of one organ negatively affects the other (8-10). Both non-end stage CKD and the disease requiring renal-replacement therapy are independently associated with higher risk of stroke, bleeding, myocardial infarction (MI) and mortality in patients with AF (11, 12). Assessment of RF is crucial for adequate NOACs dose selection in patients with AF (6).

Reportedly, the adherence to AF guidelines in the Balkan region is low (13, 14), and data on the management of patients with AF across the RF strata are lacking. Given the differences in socio-economic and healthcare system-related features between the Balkan region and Western Europe, describing patterns of AF management in clinical practice in the Balkans may identify region-specific knowledge gaps and inform strategies for optimizing the management of patients with AF in the participating Balkan countries (15).

The aims of this study were to: (i) investigate the baseline characteristics of patients with AF across CrCl strata, (ii) determine ‘real-world’ management of AF patients according to their RF and (iii) assess potential changes in decision making on the use of NOACs according to different equations for estimation of RF.

**Methods**

The design of the BALKAN-AF survey has been previously published (15). A 14-week prospective, international, multicentre ‘snapshot’ registry of consecutive patients with electrocardiographically documented non-valvular AF was created by the Serbian Atrial Fibrillation Association (SAFA). The registry was announced to the National Cardiology Societies and Associations or Working Groups in the Balkan countries. The survey was conducted from December 2014 to February 2015 in seven Balkan countries (Albania, Bulgaria, Bosnia & Herzegovina, Croatia, Montenegro, Romania and Serbia). Individuals were enrolled into the study, irrespective whether AF was the main reason for outpatient visit or inpatient stay in the hospital. Admissions for cardioversion or AF catheter ablation were also included. Patients were treated by a cardiologist or an internal medicine specialist if cardiologist was not available. Patients were recruited by academic and non-university hospitals and outpatient health centres (a total of 49 centres) in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Montenegro, Romania and Serbia. Each country recruited university and non-university hospitals and outpatient health centres situated in different cities or rural areas. The centres were selected by the respective National Coordinator. Those centres had to accurately reflect AF management in particular country in daily clinical practice. A signed patient informed consent form was obtained before enrolment. The study protocol is consistent with the ethical guidelines of the 1975 Declaration of Helsinki.

The exclusion criteria were age <18 years, prosthetic mechanical heart valves or significant valvular disease with indication for surgical repair.

Data were documented using an electronic case report form (eCRF) designed by SAFA. The eCRF included: patient characteristics, patient presentation and healthcare setting, diagnostic procedures for AF within the last 12 months and at enrolment and AF management at enrolment and at discharge. All the cardiovascular risk factors, diseases and risk scores were defined based on individual European Society of Cardiology guidelines, other current guidelines, scientific statements and textbooks presented previously in supplementary information (13).

Following equations were used for RF assessment: (1) the CG formula for CrCl (16), (2) MDRD (17) and (3) CKD-EPI (5). Using the CG formula for CrCl patients were categorized to three groups as follows: (1) preserved/ mildly depressed RF (P-RF) ≥ 50 mL/min, (2) moderately depressed RF (MD-RF) 30-49 mL/min and (3) severely depressed RF (SD-RF) <30 mL/min. Baseline characteristics and management of patients stratified into three groups according to CG formula for CrCl were performed. The cut-off values were selected according to those used in the landmark NOAC trials (6). The same cut-offs were chosen for other equations reported in this study. We reported the proportion of patients re-allocated to each class of RF for each specific formula used for RF evaluation. Some differences are present in the number of individuals allocated to each category of RF according to different equations.

Symptoms of AF were classified according to European Heart Rhythm Association (EHRA) symptom score (ie. 1 – AF does not cause any symptoms, 2 – typical daily activity not affected by symptoms related to AF, 3 – typical daily activity affected by AF symptoms, 4 – normal daily activity discontinued) (18).

Stroke risk was estimated using the CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes, stroke/transient ischaemic attack (TIA), vascular disease, age 65 to 74 years, sex category) score (19). Bleeding risk was evaluated according to the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile International Normalised Ratio (INR), elderly (>65 years), drugs or alcohol concomitantly) score (19, 20).

Because of relatively short period of the survey systematic monitoring of centres and follow-up visits was not performed. National coordinators and investigators were responsible for verification of the consecutiveness of enrolled patients and data correctness and completeness.

**Statistical analysis**

Univariate analysis was used for both continuous and categorical variables. Categorical variables were reported as absolute frequencies and percentages, and continuous variables as mean value and standard deviation (SD). Comparison of categorical variables among RF categories was calculated using Chi-Square test. Normal distribution was checked using the Shapiro-Wilk test and a Q-Q plot. Homogeneity of variances was checked using Leven’s test. Analysis of variance was performed using one-way ANOVA with post-hoc Tukey test. The descriptive analysis included baseline characteristics of patients according to their RF using CG formula and characteristics of AF patients with HF stratified by their RF. The association of patient-, AF-, healthcare system- and management-related variables with the eGFR strata was evaluated using univariate linear regression. The variables with statistically significant association on univariate linear regression analysis were entered into multivariable linear regression model. Results are expressed as odds ratio (OR) with 95% confidence interval (CI). A two-sided pvalue of less than 0.05 was interpreted as statistically significant. All analyses were performed using SAS software version 9.4 (SAS Institute, Inc., Cary, NC, USA).

**Results**

Of 2,712 patients enrolled in seven Balkan countries, complete data on RF based on CG formula for CrCl were available for 2,062 (76.0%). Of the study cohort, 1,677 patients (81.3%) had P-RF, 308 (14.9%) had MD-RF and 77 (3.8%) had SD-RF, Table 1.

*Demographic and AF-related characteristics*

Patients with SD-RF and MD-RF were older, with higher mean EHRA symptom score, less likely to be smokers but more likely to have permanent AF than those with P-RF (all p < 0.05), Table 1.

*Physical findings and comorbidity*

Patients with SD-RF and MD-RF were more likely to have various comorbidities, such as prior stroke, coronary artery disease (CAD), heart failure (HF), DM, aortic valve disease (aortic regurgitation or stenosis), mitral valve disease (mitral regurgitation or stenosis), hypertrophic cardiomyopathy (HCM), chronic obstructive pulmonary disease (COPD), anaemia and malignancy than subjects with P-RF (all p<0.05), Table 1. There was no significant difference in terms of prior bleeding history across the groups, Table 1.

*Stroke and bleeding risk factors*

Mean CHA2DS2-VASc and HAS-BLED score values were higher in patients with SD-RF and MD-RF than in patients with P-RF (all p <0.05), Table 1. The proportion of patients with CHA2DS2-VASc score of ≥ 2 and HAS-BLED score of ≥ 3 was higher in patients with SD-RF and MD-RF than in patients with P-RF (both p<0.001), Table 1.

*AF management settings*

In AF patients with SD-RF and MD-RF, the arrythmia was less often the main reason for hospitalization at enrolling visit than in those with P-RF (p<0.001); the former were more likely to be hospitalized for HF than those with P-RF (p <0.001), Table 2. Most patients were managed by a cardiologist in an academic healthcare facility and in hospital-based centre, Table 2.

*Diagnostic assessment*

Patients with SD-RF and MD-RF were less likely to have thyroid hormones assessment, transthoracic echocardiography, exercise stress testing and Holter monitoring at enrolling visit than those with P-RF (all p<0.05), Table 2.

*The multivariate predictors of decreasing CrCl according to subgroups based on CG formula at baseline*

Decreasing CrCl according to subgroups based on CG formula was significantly associated with HF, anaemia, mean CHA2DS2-VASc score, mean HAS-BLED score and the use of loop diuretics on multivariable analysis, (all p <0.001) Supporting Table 1. It was also significantly negatively associated with the use of rhythm control strategy, beta-blockers and angiotensin-converting enzyme inhibitors (ACE-I) on multivariable analysis (all p <0.001), Supporting Table 1.

*Stroke prevention strategies*

Patients with SD-RF and MD-RF were less likely to receive oral anticoagulant therapy (OAC) alone or in combination with antiplatelet drug(s), and more likely to use no antithrombotic therapy or single antiplatelet therapy (SAPT) alone than patients with P-RF (all p <0.05), Table 2.

Patients with SD-RF and MD-RF with HAS-BLED score value of ≥ 3 were more likely to receive single antiplatelet therapy (SAPT) alone or no anticoagulation compared to their P-RF counterparts. Of SD-RF patients with a CHA2DS2-VASc of ≥ 2, only 58.4% received OAC, and 41.6% were treated with SAPT alone or received no antithrombotic therapy, Figure 1.

*Arrhythmia-directed management strategies*

Patients with SD-RF and MD-RF were less likely to receive rhythm control strategy, AF catheter ablation, electrical cardioversion (ECV), propafenone and beta-blockers, and more likely to receive rate control strategy than those with P-RF (all p<0.05), Table 2.

*Other therapies*

Patients with SD-RF and MD-RF are less likely to be medicated with ACE-I and statins, and more likely to be treated with loop diuretics than patients with P-RF, (all p<0.05), Table 2. Interestingly, there was no significant difference in AT1 receptor inhibitors use across the groups, Table 2.

*Patients re-allocated to a different RF category*

Using the MDRD formula, 7 patients (0.3%) were re-classified to another RF category and, with CKD-EPI formula, a change in RF category occurred in 17 patients (0.8%), Table 3.

*Characteristics of AF patients with HF according to their RF*

Patients with SD-RF and MD-RF with HF had higher mean HAS-BLED score than patients with P-RF (p <0.001). They were more likely to have anaemia and to receive no antithrombotic therapy and SAPT alone than patients with P-RF (all p<0.05). Individuals with SD-RF and MD-RF with HF were less likely to be male, to had prior PCI/ stenting, hypercholesterolemia and to be medicated with OAC overall, OAC alone, beta-blockers, ACE-I and AT1 receptor blockers than patients with P-RF (all p <0.05), Supporting Table 2.

**Discussion**

This study provides novel insights into clinical practice from the largest published prospective AF registry from the Balkans, a European region that has been under-represented in many prior studies. In our study, 3.8% of enrolled patients had SD-RF, in line with other registries where the prevalence of patients with SD-RF ranged from 2.0% to 3.7% (11, 21, 22).

The main findings of our study were as follows: *i*) different demographic, cardiovascular risk and AF-related profile of patients according to RF, *ii*) differences in the management of AF across the RF categories, including lower use of OAC for stroke prevention in patients with SD-RF and MD-RF than in those with P-RF, whereas the use of rate control strategy, SAPT alone and no antithrombotic therapy was higher in subjects with SD-RF and MD-RF than in those with P-RF, and (*iii*) no profound differences in terms of NOAC dosing or avoidance of prescription with the use of MDRD or CKD-EPI instead of CG formula.

*Demographic, cardiovascular risk and AF-related profile*

In this study sex distribution among the different subgroups is unexpected. Patients with preserved/mildly depressed renal function (RF) were more likely to be men, whilst patients with moderately and severely depressed RF were more likely to be women. However, the number of patients with preserved/mildly depressed RF is greater than those with moderately or severely depressed RF, thus the latter can be underpowered. Moreover, patients in the BALKAN-AF dataset are more likely to be men, thus women may be underpowered in the group with preserved/ mildly depressed RF which is the largest group.

Patients with SD-RF and MD-RF were older, similar to other reports (23), and more symptomatic than those with P-RF. The higher mean EHRA symptom score in patients with SD-RF and MD-RF may reflect higher burden of comorbid conditions. In contrast to our study, AF patients with severely compromised RF were more frequently asymptomatic in another study (22). In our cohort, 23% of patients with MD-RF and 28% of those with SD-RF had first-diagnosed AF. Reportedly, up to 45% of patients with moderate to severe CKD may have newly-diagnosed AF (23).

A pattern similar to our study was also seen in a Chinese cross-sectional survey (3) where patients with low eGFR were older, more likely to have cardiovascular disease (among others, hypertension, and DM) than subjects without indicators of kidney damage.

In our study, patients with SD-RF and MD-RF were more likely to have HF than those with P-RF. This was also seen in other studies (22, 23). Baseline renal impairment and worsening of RF occurred frequently in patients with acute and chronic HF. Moreover, any degree of renal function impairment should be considered as significant risk stratifier in patients with HF (24).

*Stroke and bleeding risk and stroke prevention*

In our study, patients with SD-RF and MD-RF were older, with more concomitant diseases including HF, hypertension, DM, prior stroke than those with P-RF and therefore were more likely to have higher stroke and bleeding risk. Those findings are consistent with prior datasets (23).

In our study, the proportion of patients with SD-RF and MD-RF medicated with OAC (66% and 58%, respectively) was lower than in a recent European registry (22). However, in the Danish nationwide cohort and the Swedish AF Cohort study, the use of VKA among CKD patients was lower than in our study (11, 25), with a high prevalence of no antithrombotic therapy or use of antiplatelets only in patients with SD-RF and MD-RF. Despite increased stroke risk in patients with SD-RF, 41.6% of these patients was not anticoagulated in the Balkan region (26). Importantly, guideline-adherent anticoagulant therapy is associated with significantly better outcomes among AF patients (27). The inappropriately low use of OAC in patients with SD-RF and MD-RF is a significant knowledge gap in AF management in daily clinical practice in the Balkans. In our study, the quality of anticoagulation was poor with less than a quarter of patients having a Time in Therapeutic Range >65%. In one nationwide observational cohort study (28), patients with CKD and CHA2DS2-VASc score ≥ 2 had significantly lower risk of all-cause mortality with vs. without warfarin treatment for stroke prevention. In the Balkan region, management with NOAC was less prevalent in patients with SD-RF and MD-RF, partly owing to a lack of appropriate NOAC reimbursement policy in some Balkan countries. However, 5% of patients with SD-RF were medicated with NOAC despite contraindications (6, 26). Patients with AF and CKD had increased risk of bleeding (1, 29). However, only one patient received an alternative to OAC (i.e., left atrial appendage occlusion).

*Arrhythmia-directed management strategies*

In the BALKAN-AF survey, patients with SD-RF and MD-RF were more likely to receive rate control strategy whilst patients with P-RF were more likely to undergo a rhythm control strategy. This approach may be related to the perception of greater odds of irreversible substrate for AF in patients with SD-RF and MD-RF. Similarly, in the European Heart Rhythm Association Survey, rhythm control strategy was not preferred in patients with more advanced CKD, probably due to the lower expected success rate and limited data on safety of antiarrhythmic drugs in those patients (30). The prevalence of ECV across 3 subgroups was very low. Despite higher prevalence of permanent AF in patients with SD-RF and MD-RF, there were no significant differences in amiodarone use across 3 RF categories. Moreover, amiodarone may be overused in the Balkan region, possibly representing another knowledge gap in the real-world management of AF patients in the region.

In our study, patients with SD-RF and MD-RF were less likely to have AF catheter ablation than those with P-RF. However, AF catheter ablation tends to be increasingly used for rhythm control globally, including challenging patients with complex comorbidities (1). Maintenance of sinus rhythm after AF catheter ablation in patients with SD-RF has been shown to be associated with a significant improvement in RF (31). However, the risk of vascular complications associated with ablation is elevated in CKD patients in comparison with patients with normal RF (32).

*Different equations for estimating RF*

In our cohort, no profound differences would appear in terms of NOAC dosing or avoidance of prescription using MDRD and CKD-EPI formula instead of the CG equation. Only <1% of patients using MDRD formula and <1% of those using CKD-EPI formula would be affected by changes in NOAC dosing or avoidance of NOACs. Importantly, the precision of CG formula in estimating RF is questionable, especially among the elderly or those with increased body mass index (BMI) (33). In a comparative study (34), CG formula provided less accurate estimation of GFR than CKD-EPI and MDRD.

However, another study (35) showed that changes in NOAC therapy could appear using GFR formulas rather than CrCl in 16.9% of patients using MDRD formula and in 14.7% of subjects using CKD-EPI. The most important changes in RF assessment were revealed in patients aged ≥ 75 years, but also BMI had a significant impact.

*Limitations*

This study is limited by its observational design, and follow-up data were not collected. There are no data regarding patient/prescriber treatment preferences. Possible selection bias may appear owing to variable healthcare setting in participating countries. Differences in healthcare systems in different countries could have influenced the availability of specific drugs (e.g., NOACs). A status of compliance with guidelines may vary according to countries. However, we have analysed the totality of data and country-specific analyses are planned.

Information regarding dose adjustment with digoxin and sotalol is not collected. Albuminuria, which is a component for the evaluation of kidney function was not assessed. Moreover, physicians knew that their recommendations on diagnostic assessment and treatment would be recorded. Registries are likely to attract selected highly motivated patients and their treatment at enrolling visit may express higher compliance. However, because of enrolment of consecutive patients, the probability for a physician to recruit mainly patients with higher compliance is limited. Future prospective studies are needed to complement our results.

*Strengths*

Strengths of the study are the Balkan study setting and the prospective study design complementing published trials and registries.

**Conclusions**

In the BALKAN-AF survey, patients with SD-RF and MD-RF were older, more symptomatic, had higher stroke and bleeding risk and more comorbidities than those with P-RF. They were less likely to receive OAC, AF catheter ablation or ECV, and more likely to use rate control strategy, SAPT alone and no antithrombotic therapy than subjects with P-RF. There would be no profound differences in terms of NOAC dosing or avoidance of prescription using MDRD and CKD-EPI formula. Our study highlighted important local knowledge gaps in clinical practice that may inform targeted education interventions.

**Acknowledgements**

We thank all BALKAN-AF investigators for their hard work.

**Funding**

BALKAN-AF survey was not sponsored or funded.

**Conflict of Interest Statement**

Dr Kozieł declares no Conflict of Interests for this article.

Dr Simovic declares no Conflict of Interests for this article.

Dr Pavlović declares no Conflict of Interests for this article.

Professor Nedeljkovic declares no Conflict of Interests for this article.

Dr Kocijancic declares no Conflict of Interests for this article.

Dr Paparisto declares no Conflict of Interests for this article.

Professor Music declares no Conflict of Interests for this article.

Dr Dan declares no Conflict of Interests for this article.

Assist. Prof. Manola declares no Conflict of Interests for this article.

Professor Kusljugic declares no Conflict of Interests for this article.

Professor Trendafilova declares no Conflict of Interests for this article.

Professor G.A. Dan has been consultant for Boehringer Ingelheim, Bayer, Pfizer and Sanofi. Small speaker fees were received.

Professor Lip has been a consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon, and Daiichi-Sankyo. He has been a speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally.

Professor Potpara has been a consultant for Bayer/Jansen and BMS/Pfizer (no fees).

**References**

1. Boriani G, Savelieva I, Dan GA, Deharo JC, Ferro C, Israel CW, et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace. 2015;17(8):1169-96.

2. Hart RG, Eikelboom JW, Brimble KS, McMurtry MS, Ingram AJ. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol. 2013;29(7 Suppl):S71-8.

3. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815-22.

4. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165-80.

5. Levin A, Stevens PE, Bilous RW , Coresh J , De Francisco ALM, PE DJ, et al. Kidney disease:  Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease . 2013; 3(1). p. 1-150.

6. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace. 2018;20(8):1231-42.

7. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62.

8. Bansal N, Zelnick LR, Alonso A, Benjamin EJ, de Boer IH, Deo R, et al. eGFR and Albuminuria in Relation to Risk of Incident Atrial Fibrillation: A Meta-Analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study. Clin J Am Soc Nephrol. 2017;12(9):1386-98.

9. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009;119(10):1363-9.

10. Watanabe H, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J. 2009;158(4):629-36.

11. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367(7):625-35.

12. King A. Atrial fibrillation: HAS-BLED--a new risk score to predict bleeding in patients with AF. Nat Rev Cardiol. 2011;8(2):64.

13. Potpara TS, Dan GA, Trendafilova E, Goda A, Kusljugic Z, Manola S, et al. Stroke prevention in atrial fibrillation and 'real world' adherence to guidelines in the Balkan Region: The BALKAN-AF Survey. Sci Rep. 2016;6:20432.

14. Potpara TS, Trendafilova E, Dan GA, Goda A, Kusljugic Z, Manola S, et al. The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey. Adv Ther. 2017;34(8):2043-57.

15. Potpara TS, Lip GY. Patterns in atrial fibrillation management and 'real-world' adherence to guidelines in the Balkan Region: an overview of the Balkan-atrial fibrillation survey. Eur Heart J. 2015;36(30):1943-4.

16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.

17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-70.

18. Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P, et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace. 2014;16(7):965-72.

19. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962.

20. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-100.

21. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013;8(5):e63479.

22. Boriani G, Laroche C, Diemberger I, Popescu MI, Rasmussen LH, Petrescu L, et al. Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes. Sci Rep. 2016;6:30271.

23. Goto S, Angchaisuksiri P, Bassand JP, Camm AJ, Dominguez H, Illingworth L, et al. Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. J Am Heart Assoc. 2019;8(3):e010510.

24. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35(7):455-69.

25. Friberg L, Benson L, Lip GYH. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. European Heart Journal. 2014;36(5):297-306.

26. Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest. 2018;154(5):1121-201.

27. Lip GYH, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan G-A, et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. EP Europace. 2015;17(12):1777-86.

28. Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol. 2014;64(23):2471-82.

29. Potpara TS, Lip GY. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk. Prog Cardiovasc Dis. 2015;58(2):177-94.

30. Potpara TS, Lenarczyk R, Larsen TB, Deharo JC, Chen J, Dagres N. Management of atrial fibrillation in patients with chronic kidney disease in Europe Results of the European Heart Rhythm Association Survey. Europace. 2015;17(12):1862-7.

31. Navaravong L, Barakat M, Burgon N, Mahnkopf C, Koopmann M, Ranjan R, et al. Improvement in estimated glomerular filtration rate in patients with chronic kidney disease undergoing catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2015;26(1):21-7.

32. Roberts PR, Green D. Arrhythmias in chronic kidney disease. Heart. 2011;97(9):766-73.

33. Cirillo M, Anastasio P, De Santo NG. Relationship of gender, age, and body mass index to errors in predicted kidney function. Nephrol Dial Transplant. 2005;20(9):1791-8.

34. Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol. 2010;5(6):1003-9.

35. Malavasi VL, Pettorelli D, Fantecchi E, Zoccali C, Laronga G, Trenti T, et al. Variations in clinical management of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation according to different equations for estimating renal function : Post hoc analysis of a prospective cohort. Intern Emerg Med. 2018;13(7):1059-67.

**Table 1. Baseline characteristics of patients according to renal function**

\*>4 units of alcohol per day.

\*\* Well controlled hypertension - an average systolic blood pressure < 140 mmHg or an average diastolic blood pressure < 90 mmHg, among patients with hypertension.

\*\*\*Aortic regurgitation or stenosis.

\*\*\*\*Mitral regurgitation or stenosis.

AF, atrial fibrillation; BMI, body mass index; bpm; beats per minute. CAD, coronary artery disease; CHA2DS2-VASc: congestive heart failure, hypertension, age ≥ 75 years, diabetes, stroke/transient ischemic attack (TIA), vascular disease, age 65 to 74 years, sex category, COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; DCM, dilated cardiomyopathy; eGFR, estimated glomerular filtration rate; EHRA, European Heart Rhythm Association; HAS-BLED: hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile International Normalised Ratio, elderly (age > 65 years), drugs or alcohol concomitantly, HCM, hypertrophic cardiomyopathy; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; RCM, restrictive cardiomyopathy; SD, standard deviation; SBP, systolic blood pressure; TIA, transient ischaemic attack.

**Table 2. Atrial fibrillation management according to renal function**

ACE-I, angiotensin converting enzyme inhibitor; ACS, acute coronary syndrome; AF, atrial fibrillation; AV, atrioventricular, CG, Cockcroft-Gault, DAPT, dual antiplatelet therapy; ECV, electrical cardioversion; eGFR, estimated glomerular filtration rate; HF, heart failure, NOAC, non-vitamin K oral anticoagulants; OAC, oral anticoagulants; PM, pacemaker; VKA, vitamin K antagonist.

**Table 3. Number and proportion of patients allocated to the different classes of renal function, changed according to equations, for renal function assessment, different than CG**

Bold represents MD-RF, italics represents SD-RF.

CG, Cockcroft-Gault, CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration group, CrCl, creatinine clearance, MDRD, Modification of Diet in Renal Disease, MD-RF, moderately depressed renal function, P-RF, preserved/mildly depressed renal function, SD-RF, severely depressed RF.

**Figure 1. Stroke prevention strategies in patients with AF according to CrCl based on CG formula**

AF, atrial fibrillation, CHA2DS2-VASc: congestive heart failure, hypertension, age ≥ 75 years, diabetes, stroke/transient ischaemic attack (TIA), vascular disease, age 65 to 74 years, sex category, CG, Cockcroft-Gault, CrCl, creatinine clearance, eGFR; estimated glomerular filtration rate, HAS-BLED: hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile International Normalised Ratio, elderly (age > 65 years), drugs or alcohol concomitantly, OAC; oral anticoagulants.

**APPENDIX**

**SUPPLEMENTARY MATERIAL**

**Treatment implications of renal disease in patients with atrial fibrillation: the BALKAN-AF survey**

Monika Kozieł, Stefan Simovic, Nikola Pavlovic, Milan Nedeljkovic, Aleksandar Kocijancic, Vilma Paparisto, Ljilja Music, Elina Trendafilova, Anca Rodica Dan, Sime Manola, Zumreta Kusljugic, Gheorghe-Andrei Dan, \*Gregory Y.H. Lip, \*Tatjana S. Potpara, on behalf of the BALKAN-AF Investigators.

**Supporting Table 1. Independent predictors of decreasing creatinine clearance according to CG equation in patients with AF**

|  |  |  |
| --- | --- | --- |
|  | Univariate analysis | Multivariate analysis |
| Variable | **Estimate** | **p-value** | **Estimate** | **p-value** |
| BMI (mean) | -0.022 | <0.001 | -0.021 | 0.057 |
| Healthcare facility in capital city | -0.064 | 0.003 | -0.063 | 0.062 |
| University healthcare facility | -0.018 | 0.588 | -0.021 | 0.811 |
| Hospital-based centre | -0.017 | 0.668 | -0.019 | 0.771 |
| Treatment by cardiologist | -0.054 | 0.053 | -0.063 | 0.613 |
| Paroxysmal AF | -0.061 | 0.007 | -0.071 | 0.057 |
| Permanent AF | 0.084 | <0.001 | 0.089 | 0.053 |
| HF | 0.223 | <0.001 | 0.221 | <0.001 |
| Hypertension | 0.017 | 0.512 | 0.026 | 0.511 |
| Prior MI | 0.088 | 0.047 | 0.076 | 0.056 |
| Coronary artery disease | 0.068 | 0.004 | 0.074 | 0.077 |
| Diabetes mellitus | 0.080 | 0.002 | 0.070 | 0.132 |
| Mitral valve disease | 0.115 | <0.001 | 0.121 | 0.066 |
| Dilated cardiomyopathy | -0.010 | 0.816 | -0.015 | 0.912 |
| COPD | 0.112 | <0.001 | 0.213 | 0.141 |
| Thyroid disease | 0.033 | 0.347 | 0.048 | 0.062 |
| Anaemia | 0.322 | <0.001 | 0.350 | <0.001 |
| Obesity | -0.063 | 0.016 | -0.079 | 0.054 |
| CHA2DS2-VASc (mean) | 0.087 | <0.001 | 0.055 | <0.001 |
| HAS-BLED (mean) | 0.130 | <0.001 | 0.124 | <0.001 |
| Rate control | 0.096 | <0.001 | 0.104 | 0.057 |
| Rhythm control | -0.122 | <0.001 | -0.126 | <0.001 |
| AF catheter ablation | -0.178 | 0.007 | -0.261 | 0.190 |
| ECV | -0.170 | 0.005 | -0.270 | 0.061 |
| OAC (overall) | -0.122 | <0.001 | -0.167 | 0.057 |
| VKA | -0.053 | 0.018 | -0.077 | 0.166 |
| NOAC | -0.072 | 0.021 | -0.095 | 0.423 |
| ASA | 0.047 | 0.061 | 0.081 | 0.788 |
| Beta-blockers | -0.082 | 0.001 | -0.073 | <0.001 |
| Digoxin | 0.047 | 0.074 | 0.057 | 0.640 |
| ACE-I | -0.104 | <0.001 | -0.087 | <0.001 |
| AT1 receptor blockers | -0.085 | 0.006 | -0.092 | 0.316 |
| Loop diuretics | 0.154 | <0.001 | 0.150 | <0.001 |

ACE-I, angiotensin converting enzyme inhibitor, AF, atrial fibrillation; ASA, acetylsalicylic acid; BMI, body mass index; CG, Cockcroft-Gault; CHA2DS2-VASc: congestive heart failure, hypertension, age ≥ 75 years, diabetes, stroke/transient ischaemic attack (TIA), vascular disease, age 65 to 74 years, sex category, COPD, chronic obstructive pulmonary disease; ; eGFR, estimated glomerular filtration rate; ; HAS-BLED: hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile International Normalised Ratio, elderly (age > 65 years), drugs or alcohol concomitantly; HF, heart failure; MI, myocardial infarction; NOAC, non-vitamin K oral anticoagulants OAC; oral anticoagulants; VKA, vitamin K antagonist.

**Supporting Table 2. Characteristics of AF patients with HF according to renal function**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | CG ≥ 50 ml/minn = 594(71.4%) | CG 30-49 ml/minn = 179(21.5%) | CG <30 ml/minn = 59 (7.1%) | p value (among the 3 groups) |
| Age, mean (SD), yrs | 69.3±9.7 | 78.5±8.0 | 78.6±8.4 | 0.271 |
| BMI, mean (SD), kg/m² | 28.6±4.9 | 26.1±3.9 | 25.9±4.3 | <0.001 |
| Male sex, n (%) | 387 (65.2) | 67 (37.4) | 27 (45.8) | <0.001 |
| EHRA symptom score, mean (SD) | 2.4±0.8 | 2.4±0.8 | 2.4±0.8 | 0.897 |
|  EHRA I, n (%) | 58 (9.8) | 22 (12.3) | 8 (13.6) | <0.001 |
|  EHRA II, n (%) | 304 (51.2) | 78 (43.6) | 21 (35.6) | <0.001 |
|  EHRA III, n (%) | 191 (32.2) | 70 (39.1) | 26 (44.1) | <0.001 |
|  EHRA IV, n (%) | 41 (6.9) | 9 (5.0) | 4 (6.8) | 0.604 |
| Medical history, n (%) |  |  |  |  |
|  Hypertension | 453 (76.3) | 146 (81.6) | 46 (78.0) | 0.899 |
|  Previous stroke | 75 (12.6) | 21 (11.7) | 13 (22.0) | 0.087 |
|  Previous TIA | 14 (2.4) | 7 (3.9) | 1 (1.7) | 0.058 |
|  CAD | 254 (42.8) | 73 (40.8) | 25 (42.4) | 0.071 |
|  MI | 128 (21.5) | 37 (20.7) | 14 (23.7) | 0.057 |
|  Prior PCI/stenting | 57 (9.6) | 15 (8.4) | 2 (3.4) | <0.001 |
|  Diabetes mellitus | 179 (30.1) | 65 (36.3) | 19 (32.2) | <0.001 |
|  Prior bleeding | 36 (6.1) | 15 (8.4) | 4 (6.8) | 0.086 |
|  COPD | 124 (20.9) | 31 (17.3) | 14 (23.7) | <0.001 |
|  PAD | 29 (4.9) | 7 (3.9) | 2 (3.4) | 0.867 |
|  Hypercholesterolemia | 234 (39.4) | 60 (33.5) | 21 (35.6) | 0.007 |
|  Anaemia | 87 (14.6) | 61 (34.1) | 23 (39.0) | <0.001 |
|  Malignancy | 22 (3.7) | 19 (10.6) | 2 (3.4) | 0.068 |
|  Obesity | 144 (24.2) | 49 (27.4) | 8 (13.6) | 0.163 |
| CHA2DS2-VASc, mean (SD) | 4.0±1.6 | 5.1±1.3 | 5.0±1.5 | 0.059 |
| CHA2DS2-VASc ≥ 2 | 568 (95.6) | 177 (99.8) | 58 (98.3) | <0.001 |
| HAS-BLED, mean (SD) | 2.1±1.2 | 2.9±1.2 | 3.2±0.9 | <0.001 |
| HAS-BLED ≥3 | 192 (32.2) | 107 (59.8) | 46 (78.0) | <0.001 |
| *Stroke prevention (at enrolling visit), n (%)* |  |  |  |  |
| No antithrombotic therapy | 43 (7.2) | 19 (10.6) | 10 (16.9) | <0.001 |
| Overall OAC | 471 (79.3) | 114 (63.7) | 35 (59.3) | <0.001 |
| OAC alone | 397 (66.8) | 99 (55.3) | 31 (52.5) | 0.003 |
| VKA  | 395 (66.8) | 88 (49.2) | 33 (55.9) | <0.001 |
| NOAC | 76 (12.8) | 26 (14.5) | 2 (3.4) | 0.001 |
| Single antiplatelet therapy alone | 53 (8.9) | 34 (19.0) | 11 (18.6) | 0.004 |
| DAPT alone | 27 (4.5) | 12 (6.7) | 3 (5.1) | 0.595 |
| Dual antithrombotic therapy | 59 (9.9) | 10 (5.6) | 4 (6.8) | 0.164 |
| Triple antithrombotic therapy | 15 (2.5) | 5 (2.8) | 0 (0.0) | 0.082 |
| Rhythm control | 104 (17.5) | 31 (17.3) | 10 (16.9) | 0.067 |
| Rate control | 459 (77.3) | 134 (74.9) | 40 (67.8) | <0.001 |
| *Pharmacological AF therapies (at enrolment), n (%)* |  |  |  |  |
| Digoxin | 230 (38.7) | 71 (39.7) | 9 (15.3) | <0.001 |
| Beta-blockers | 445 (74.9) | 120 (67.0) | 38 (64.4) | 0.002 |
| ACE-I | 293 (49.3) | 71 (39.7) | 21 (35.6) | 0.001 |
| AT1 receptor blockers | 133 (22.4) | 36 (20.1) | 10 (16.9) | 0.005 |
| Loop diuretics | 437 (73.6) | 123 (68.7) | 44 (74.6) | 0.007 |

ACE-I, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; BMI, body mass index; CAD, coronary artery disease; CHA2DS2-VASc: congestive heart failure, hypertension, age ≥ 75 years, diabetes, stroke/transient ischemic attack (TIA), vascular disease, age 65 to 74 years, sex category, COPD, chronic obstructive pulmonary disease; DAPT, dual antiplatelet therapy; EHRA, European Heart Rhythm Association; HAS-BLED: hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile International Normalised Ratio, elderly (age > 65 years), drugs or alcohol concomitantly, HF, heart failure; MI, myocardial infarction; NOAC, non-vitamin K oral anticoagulants; OAC, oral anticoagulation; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; VKA, vitamin K antagonists; SD, standard deviation; TIA, transient ischaemic attack.